drugset / Trial / NCT04405843

Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial)

NCT04405843

Phase 2/3 Completed 476 enrolled Centro de Estudios en Infectogía Pediatrica
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Double blind, placebo controlled, randomized clinical trial to evaluate the efficacy of ivermectin in preventing progression of disease in adult patients with early stages of COVID-19

Timeline

Start
2020-07-14
Primary completion
2020-12-21
Completion
2020-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivermectin Small molecule 300 ug/kg Oral

Indications